CAMP4 THERAPEUTICS CORPORATION (CAMP) - Total Liabilities
Based on the latest financial reports, CAMP4 THERAPEUTICS CORPORATION (CAMP) has total liabilities worth $74.56 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CAMP asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
CAMP4 THERAPEUTICS CORPORATION - Total Liabilities Trend (1985–2025)
This chart illustrates how CAMP4 THERAPEUTICS CORPORATION's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see CAMP total assets.
CAMP4 THERAPEUTICS CORPORATION Competitors by Total Liabilities
The table below lists competitors of CAMP4 THERAPEUTICS CORPORATION ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Symphony International Holdings Ltd
LSE:SIHL
|
UK | $16.41 Million |
|
KidariStudio Inc
KO:020120
|
Korea | ₩138.24 Billion |
|
Kolibri Global Energy Inc. Common stock
NASDAQ:KGEI
|
USA | $85.05 Million |
|
Iberpapel Gestion SA
MC:IBG
|
Spain | €65.38 Million |
|
GSI Technology Inc
NASDAQ:GSIT
|
USA | $16.19 Million |
|
Humasis Co. Ltd
KQ:205470
|
Korea | ₩90.75 Billion |
|
Ming Shing Group Holdings Limited Ordinary Shares
NASDAQ:PMA
|
USA | $10.65 Million |
|
Steamships Trading Company Ltd
AU:SST
|
Australia | AU$785.45 Million |
Liability Composition Analysis (1985–2025)
This chart breaks down CAMP4 THERAPEUTICS CORPORATION's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See CAMP4 THERAPEUTICS CORPORATION balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.71 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CAMP4 THERAPEUTICS CORPORATION's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CAMP4 THERAPEUTICS CORPORATION (1985–2025)
The table below shows the annual total liabilities of CAMP4 THERAPEUTICS CORPORATION from 1985 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $70.10 Million | +362.34% |
| 2024-12-31 | $15.16 Million | -91.51% |
| 2023-12-31 | $178.68 Million | -0.78% |
| 2022-12-31 | $180.08 Million | -44.09% |
| 2021-12-31 | $322.11 Million | -5.95% |
| 2020-12-31 | $342.50 Million | -4.30% |
| 2019-12-31 | $357.89 Million | -10.07% |
| 2018-12-31 | $397.97 Million | +45.20% |
| 2017-12-31 | $274.08 Million | +12.47% |
| 2016-12-31 | $243.68 Million | +25.02% |
| 2015-12-31 | $194.92 Million | +280.46% |
| 2014-12-31 | $51.23 Million | +11.09% |
| 2013-12-31 | $46.12 Million | +38.82% |
| 2012-12-31 | $33.22 Million | +25.35% |
| 2011-12-31 | $26.50 Million | -30.04% |
| 2010-12-31 | $37.88 Million | +0.34% |
| 2009-12-31 | $37.75 Million | -18.72% |
| 2008-12-31 | $46.45 Million | -33.28% |
| 2007-12-31 | $69.62 Million | -11.26% |
| 2006-12-31 | $78.45 Million | +177.83% |
| 2005-12-31 | $28.24 Million | -26.59% |
| 2004-12-31 | $38.47 Million | +19.17% |
| 2003-12-31 | $32.28 Million | +4.21% |
| 2002-12-31 | $30.97 Million | +62.10% |
| 2001-12-31 | $19.11 Million | -2.17% |
| 2000-12-31 | $19.53 Million | -28.87% |
| 1999-12-31 | $27.46 Million | +418.08% |
| 1998-12-31 | $5.30 Million | -13.11% |
| 1997-12-31 | $6.10 Million | +12.96% |
| 1996-12-31 | $5.40 Million | -44.33% |
| 1995-12-31 | $9.70 Million | +34.72% |
| 1994-12-31 | $7.20 Million | -2.70% |
| 1993-12-31 | $7.40 Million | -14.94% |
| 1992-12-31 | $8.70 Million | +61.11% |
| 1991-12-31 | $5.40 Million | +92.86% |
| 1990-12-31 | $2.80 Million | -28.21% |
| 1989-12-31 | $3.90 Million | +39.29% |
| 1988-12-31 | $2.80 Million | -48.15% |
| 1987-12-31 | $5.40 Million | 0.00% |
| 1986-12-31 | $5.40 Million | -38.64% |
| 1985-12-31 | $8.80 Million | -- |
About CAMP4 THERAPEUTICS CORPORATION
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was f… Read more